 |
|
Evolving Antiepileptic Drug Treatment in Juvenile Myoclonic Epilepsy
Avinash Prasad, MD;
Ruben I. Kuzniecky, MD;
Robert C. Knowlton, MD;
Tim E. Welty, PharmD;
Roy C. Martin, PhD;
M. Mendez, MD;
Raymond E. Faught, MD
Arch Neurol. 2003;60:1100-1105.
Background In the face of availability of newer antiepileptic drugs (AEDs) such as lamotrigine and topiramate, there is need to reassess the role of older AEDs in the treatment of juvenile myoclonic epilepsy (JME).
Objectives To explore whether lamotrigine and topiramate monotherapy or polytherapy can be effective options in the treatment of JME, and to determine whether older AEDs, such as phenytoin and carbamazepine, have a role in the treatment of JME.
Design A retrospective cohort study.
Setting A large academic teaching hospital.
Patients Seventy-two consecutive JME patients treated with valproic acid, lamotrigine, topiramate, phenytoin, or carbamazepine between April 1, 1991, and March 31, 2001.
Methods We compared the efficacy of valproic acid, lamotrigine, and topiramate monotherapy or polytherapy in the control of different seizure types of JME, and compared their efficacy and tolerability with the efficacy and tolerability of phenytoin and carbamazepine.
Results Seizure outcome did not differ when patients receiving valproic acid monotherapy (n = 36) were compared with those receiving lamotrigine monotherapy (n = 14), and when patients receiving valproic acid polytherapy (n = 22) were compared with those receiving lamotrigine polytherapy (n = 21) or topiramate polytherapy (n = 15) (P>.05 for all). The combined data of myoclonic seizure control by all 3 AEDs were poorer when compared with the combined data of generalized tonic-clonic seizure control by all 3 AEDs (P = .03), but not when compared with the combined data of absence seizure control by all 3 AEDs (P = .43). Valproic acid, lamotrigine, and topiramate, when compared with phenytoin or carbamazepine, demonstrated significantly better control of myoclonic seizures (P<.01 for all), but not of generalized tonic-clonic seizures (P>.11 for all).
Conclusions Lamotrigine and topiramate are effective alternative options to valproic acid in the treatment of JME. Lamotrigine is an effective option as monotherapy and polytherapy. Topiramate is an effective option as polytherapy, but more data are needed to determine if it is an effective option as monotherapy. More effective therapy is needed to improve myoclonic seizure control. Older AEDs, such as phenytoin and carbamazepine, may not be indicated in JME patients.
From the Epilepsy Division, the Department of Neurology, University of Alabama School of Medicine (Drs Prasad, Kuzniecky, Knowlton, Martin, Mendez, and Faught), and the Department of Pharmacy, McWhorter School of Pharmacy, Samford University (Dr Welty), Birmingham, Ala. Dr Faught is a consultant to Abbott Laboratories, North Chicago, Ill; Ortho-McNeil, Raritan, NJ; Novartis, East Hanover, NJ; GlaxoSmithKline, Research Triangle Park, NC. Dr Faught has received honoraria for speaking from Abbott Laboratories, North Chicago, Ill; Ortho-McNeil, Raritan, NJ; GlaxoSmithKline, Research Triangle Park, NC; Shire, Florence, Ky. Dr Faught has received research support from Abbott Laboratories, North Chicago, Ill; Ortho-McNeil, Raritan, NJ. Dr Prasad is a consultant to Ortho-McNeil, Raritan, NJ; and Novartis, East Hanover, NJ.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Topiramate in Patients With Juvenile Myoclonic Epilepsy
Biton et al.
Arch Neurol 2005;62:1705-1708.
ABSTRACT
| FULL TEXT
Initial treatment of epilepsy with antiepileptic drugs: Pediatric issues
Sankar
Neurology 2004;63:S30-S39.
ABSTRACT
| FULL TEXT
Evolving Antiepileptic Drug Treatment in Juvenile Myoclonic Epilepsy
Grunewald et al.
Arch Neurol 2004;61:1328-1328.
FULL TEXT
Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders
Wheless and Bourgeois
J Child Neurol 2004;19:S39-S48.
ABSTRACT
Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders
Wheless and Bourgeois
J Child Neurol 2004;19:S39-S48.
ABSTRACT
|
